Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955305 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT00955305: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00955305 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 175 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00955305, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab (CPB) work when given with or without cixutumumab in treating patients with non-small cell lung cancer that is stage IV or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Other types of monoclonal antibodies, such as cixutumumab, may find tumor cells and help kill them. It is not yet known whether giving more than one drug (combination chemotherapy) together with bevacizumab is more effective when given with or without cixutumumab in treating patients with non-small cell lung cancer.
Primary Outcome
Progression-free survival was defined as the time from randomization to progression or death without documentation of progression. For cases without progression, follow-up was censored at the date of last disease assessment without progression, unless death occurs within 3 months following the date last known progression-free, in which case the death was counted as a failure. Progression was evaluated using RECIST 1.1 criteria and defined as: 1. At least a 20% increase in the sum of the diamet
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
- BIOLOGICAL Cixutumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2010-03 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Why NCT00955305 stopped before completion
NCT00955305 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00955305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00955305 about?
NCT00955305 is a clinical study titled "Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer". This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab (CPB) work when given with or without cixutumumab in treating patients with non-small cell lung cancer that is stage IV or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel and carboplati...
What is the current status of trial NCT00955305?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2010-03. Estimated completion is 2016-11.
What interventions are being tested in trial NCT00955305?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Cixutumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00955305?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00955305's enrollment target sits among peer trials
175 396th of 2000 higher than 1,605 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia